MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease?

Movement Disorders

Volumn 30, Issue 10, 2015, Pages 1304-1305

  Öz, Gülin ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LEVODOPA; TRACER; ASPARTIC ACID; CREATINE;

DIFFERENTIAL DIAGNOSIS; EDITORIAL; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; ANALOGS AND DERIVATIVES; FEMALE; MALE; METABOLISM; PROCEDURES;

ASPARTIC ACID; CREATINE; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SUBSTANTIA NIGRA;

EID: 84941172159     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26322     Document Type: Editorial

References (19)

1. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010;16(6):653-661.
2. Stoessl AJ, Lehericy S, Strafella AP. Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. Lancet 2014;384(9942):532-544.
3. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. Journal of neurology 2000;247 Suppl 2:II11-II18.
4. Lehericy S, Sharman MA, Dos Santos CL, Paquin R, Gallea C. Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord 2012;27(7):822-830.
5. Öz G, Alger JR, Barker PB, et al. The MRS Consensus Group. Clinical proton MR spectroscopy in central nervous system disorders. Radiology 2014;270(3):658-679.
6. 1H magnetic resonance spectroscopy. Invest Radiol 1998;33(8):450-455.
7. 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 2002;17(5):917-927.
8. Baik HM, Choe BY, Son BC, et al. Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy. Eur J Radiol 2003;47(3):179-187.
9. Nie K, Zhang Y, Huang B, et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. Parkinsonism & related disorders 2013;19(3):329-334.
10. 1H-MR spectroscopy imaging study. Mov Disord 2015;30:1400-1404.
11. Mountford CE, Stanwell P, Lin A, Ramadan S, Ross B. Neurospectroscopy: the past, present and future. Chem Rev 2010;110(5):3060-3086.
12. Martin WR. Magnetic resonance imaging and spectroscopy in Parkinson's disease. Adv Neurol 2001;86:197-203.
13. Öz G, Terpstra M, Tkáč I, et al. Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med 2006;55(2):296-301.
14. Emir UE, Tuite PJ, Öz G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PloS One 2012;7(1):e30918.
15. Holshouser BA, Komu M, Moller HE, et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study. Magn Reson Med 1995;33(5):589-594.
16. Ellis CM, Lemmens G, Williams SC, et al. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology 1997;49(2):438-444.
17. Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology 1993;43(4):697-700.
18. Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC, Henchcliffe C. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease. J Neuroimaging 2015;25(1):105-110.
19. Gröger A, Chadzynski G, Godau J, Berg D, Klose U. Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. Eur Radiol 2011;21(9):1962-1969.